Johnson & Johnson vs Krystal Biotech, Inc.
JNJ vs KRYS — side-by-side comparison from reported financials. JNJ leads 5, KRYS leads 5 of 10 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Krystal Biotech, Inc.
KRYS · Healthcare
$331.61+1.32%Strained
| Metric | JNJ | KRYS |
|---|---|---|
| Price | $261.79 | $331.61 |
| Market cap | $631B | $9.82B |
| Revenue (TTM) | $97.9B | $440M |
| Revenue growth | +5.6% | +22.6% |
| Net margin | 21.5% | 54.8% |
| Free cash flow | $22.2B | $258M |
| Net cash (debt) | ($27.8B) | $818M |
| 1-year price return | +37.0% | +75.7% |
| P/E | 29.9 | 40.6 |
| P/E vs own history (cheap-side %) | 16% | 63% |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | 19% |
| CV checks passed | 10 of 11 | 7 of 11 |
| Employees | 140,800 | 295 |
Full résumé-style profiles: JNJ CV · KRYS CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.